<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04094558</url>
  </required_header>
  <id_info>
    <org_study_id>19-0957</org_study_id>
    <nct_id>NCT04094558</nct_id>
  </id_info>
  <brief_title>Validation of the Small Intestine Microbiome Aspiration (SIMBA) Capsule</brief_title>
  <official_title>Validation of the Small Intestine Microbiome Aspiration (SIMBA) Capsule</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nimble Science Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Calgary</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, open label trial to establish the ability of the SIMBA Capsule to accurately&#xD;
      obtain a sample from the small bowel of participants with IBS (10 constipation-predominant&#xD;
      (IBS-C) and 10 diarrhea-predominant (IBS-D)) and healthy participants (n=10). The accuracy of&#xD;
      targeting the small bowel will be established by visual confirmation via X-ray. The clinical&#xD;
      utility of the collected sample will be evaluated by analysis with samples obtained by the&#xD;
      current gold standard (duodenal aspirate), as well as stool analysis and LBT.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 27, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bacterial composition</measure>
    <time_frame>same day</time_frame>
    <description>1. Correlations of bacterial composition (superimposability of PLS-DA mapping) of samples collected by the SIMBA Capsule compared to small bowel aspirate and to mucosal microbiome sample obtained by brushing. (hypothesis: findings will be similar)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bacterial composition</measure>
    <time_frame>same day</time_frame>
    <description>2. Correlations of bacterial composition (superimposability of PLS-DA mapping) of samples collected by the SIMBA Capsule compared to stool sample obtained at same time. (hypothesis: findings will be different)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bacterial composition</measure>
    <time_frame>within 5 days of primary measures</time_frame>
    <description>1. Correlation of hydrogen- and methane-producing bacteria species (by 16s RNA sequencing) found by SIMBA Capsule with hydrogen and methane concentrations (peak and rise in ppm) detected by LBT and bacterial density (CFU/ml) of endoscopic aspirate.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Proof of Concept</condition>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>IBS-D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participant diagnosed with Irritable Bowel Syndrome, diarrhea predominant, confirmed by study doctors using Rome IV criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IBS-C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participant diagnosed with Irritable Bowel Syndrome, constipation predominant, confirmed by study doctors using Rome IV criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participant with no ongoing medical conditions affecting GI health.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ingestible capsule</intervention_name>
    <description>Participants will swallow capsules and collect in stool concurrent with stool samples</description>
    <arm_group_label>Healthy Control</arm_group_label>
    <arm_group_label>IBS-C</arm_group_label>
    <arm_group_label>IBS-D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sedated EGD</intervention_name>
    <description>Participants will undergo sedated esophagogastroduodenoscopy (EGD) for collection of small intestine aspirate and simultaneous saliva sample.</description>
    <arm_group_label>Healthy Control</arm_group_label>
    <arm_group_label>IBS-C</arm_group_label>
    <arm_group_label>IBS-D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Lactulose Breath Test</intervention_name>
    <description>Hydrogen and methane breath test with lactulose substrate</description>
    <arm_group_label>Healthy Control</arm_group_label>
    <arm_group_label>IBS-C</arm_group_label>
    <arm_group_label>IBS-D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Aged between 18 and 70 years.&#xD;
&#xD;
          2. Diagnosis of IBS by Rome 4 criteria (IBS groups) or no previous diagnosis of IBS or&#xD;
             suspected IBS (Control group).&#xD;
&#xD;
          3. Ability to understand and provide informed consent.&#xD;
&#xD;
          4. Ability and willingness to meet the required schedule and study interventions.&#xD;
&#xD;
          5. No planned change in diet or medical interventions during the study duration.&#xD;
&#xD;
          6. Adequate mobility to transfer repeatedly between X-ray (standing or lying), and&#xD;
             waiting (sitting).&#xD;
&#xD;
          7. Willing and able to undergo a sedated esophagogastroduodenoscopy (EGD) with aspirate&#xD;
             and brushing.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Prior gastrointestinal disease, surgery, or radiation treatment which, in the&#xD;
             investigator's opinion, would lead to intestinal structuring or obstruction with a&#xD;
             risk of capsule non-excretion (particular diseases which would be assessed on a&#xD;
             case-by-case basis would include, achalasia, eosinophilic esophagitis, Crohn's&#xD;
             disease, cancer diagnosis or treatment within the past year, or previous esophageal,&#xD;
             gastric, small intestinal, or colonic surgery. Appendectomy or cholecystectomy more&#xD;
             than 3 months prior to enrollment are acceptable).&#xD;
&#xD;
          2. Use of any medications in the previous week that could substantially alter&#xD;
             gastrointestinal motor function (e.g., opioids, prokinetics, anticholinergics,&#xD;
             laxatives), or acidity (PPI, H2RA).&#xD;
&#xD;
          3. History of oropharyngeal dysphagia or other swallowing disorder with a risk of&#xD;
             aspiration of the capsule.&#xD;
&#xD;
          4. Females of childbearing age who are not practicing birth control and/or are pregnant&#xD;
             or lactating.&#xD;
&#xD;
          5. No antibiotics, or colon cleanses/bowel prep for 2 weeks.&#xD;
&#xD;
          6. &lt; 2 bowel movements per week (Control Group).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher N Andrews</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cumming School of Medicine, University of Calgary</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lynn Wilsack, MSc</last_name>
    <phone>403 592-5045</phone>
    <email>lwilsack@ucalgary.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cumming School of Medicine, University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynn Wilsack, MSc</last_name>
      <phone>4035925045</phone>
      <email>lwilsack@ucalgary.ca</email>
    </contact>
    <contact_backup>
      <last_name>Renata Rehak, PhD</last_name>
      <phone>4032107422</phone>
      <email>rrehak@ucalgary.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Christopher N Andrews, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Woo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yasmin Nasser, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 17, 2019</study_first_submitted>
  <study_first_submitted_qc>September 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2019</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lactulose</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

